A meta-analysis on the prevalence of Charcot-Marie-Tooth disease and related inherited peripheral neuropathies

Background Charcot-Marie-Tooth disease and related inherited peripheral neuropathies (CMT & RIPNs) brings great suffering and heavy burden to patients, but its global prevalence rates have not been well described.Methods We searched major English and Chinese databases for studies reporting the prevalence of CMT & RIPNs from the establishment of the databases to September 26, 2022. Based on the age, gender, study design, study region, and disease subtype, the included studies were correspondingly synthesized for meta-analyses on the overall prevalence and/or the subgroup analyses by using pool arcsine transformed proportions in the random-effects model.Results Of the finally included 31 studies, 21 studied the whole age population and various types of CMT & RIPNs, and the others reported specific disease subtype(s) or adult or non-adult populations. The pooled prevalence was 17.69/100,000 (95% CI 12.32-24.33) for the whole age population and significantly higher for CMT1 [10.61/100,000 (95% CI 7.06-14.64)] than for other subtypes (P' < 0.001). Without statistical significance, the prevalence seemed higher in those aged >= 16 or 18 years (21.02/100,000) than in those aged < 16 years (16.13/100,000), in males (22.50/100,000) than in females (17.95/100,000), and in Northern Europe (30.97/100,000) than in other regions.Conclusion CMT & RIPNs are relatively more prevalent as CMT1 in the disease subtypes, and probably prevalent in older ages, males, and Northern Europe. More studies on the epidemiological characteristics of CMT & RIPNs with well-defined diagnosis criteria are needed to improve the prevalence evaluation and to arouse more attention to health care support.

Automated summary

Charcot-Marie-Tooth disease and related inherited peripheral neuropathies (CMT & RIPNs) cause significant suffering and burden to patients, but there is a lack of comprehensive understanding of their global prevalence rates. Further epidemiological studies with well-defined diagnostic criteria are needed to improve the assessment of prevalence and raise awareness for better healthcare support.